AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37697324 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐DST (clinical decision assessment system)
Number of subjects: 0
Study 37697324 — intervention group
Group type: COMPARATOR
Intervention: Usual paper version (control group)
Number of subjects: 0
Study 33485646 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg H7N9 IIV adjuvanted with MF59
Number of subjects: 479
Study 33485646 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 µg H7N9 IIV adjuvanted with MF59
Number of subjects: 479
Study 33485646 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg H7N9 IIV adjuvanted with MF59
Number of subjects: 479
Study 33485646 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose series on days 1, 28 and 168
Number of subjects: 479
Study 33485646 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose series on days 1, 57 and 168
Number of subjects: 479
Study 33485646 — intervention group
Group type: COMPARATOR
Intervention: Recent prior receipt of seasonal influenza vaccine
Number of subjects: 479
Study 32381048 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care bedside ultrasound (PoCUS)
Number of subjects: 242
Study 32381048 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care bedside ultrasound (PoCUS) by expert
Number of subjects: 242
Study 32381048 — intervention group
Group type: COMPARATOR
Intervention: Radiographic imaging
Number of subjects: 242
Study 35952426 — intervention group
Group type: EXPERIMENTAL
Intervention: Test agent nasal spray, administered 3 times daily over a 45 day course
Number of subjects: 556
Study 35952426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 35969169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotically delivered pain science education
Number of subjects: 20
Study 35969169 — intervention group
Group type: COMPARATOR
Intervention: Pain science education with progressive muscle relaxation
Number of subjects: 20
Study 35936366 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol combined with conventional antihypertensive therapy
Number of subjects: 80
Study 35936366 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy
Number of subjects: 80
Study 33492568 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 mg every 12 h on a 28-day cycle
Number of subjects: 26
Study 33492568 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 h on a 28-day cycle
Number of subjects: 26
Study 33492568 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (both dosages)
Number of subjects: 26
Study 32115419 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular embolization only
Number of subjects: 26
Study 35440798 — intervention group
Group type: EXPERIMENTAL
Intervention: Online positive parenting programme (PPP)
Number of subjects: 103
Study 35440798 — intervention group
Group type: COMPARATOR
Intervention: Active control group (general education)
Number of subjects: 103
Study 35440798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 33586058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-managed titration of insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0
Study 33586058 — intervention group
Group type: COMPARATOR
Intervention: Physician-managed titration of insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0
Study 36336245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin Mass Drug Administration (MDA)
Number of subjects: 1052
Study 36336245 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1052
Study 34011198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 34011198 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 32057125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment
Number of subjects: 0
Study 32057125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 0
Study 32057125 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 0
Study 34114623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid
Number of subjects: 92
Study 34114623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 92
Study 34114623 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 90 mg dosing
Number of subjects: 92
Study 34114623 — intervention group
Group type: COMPARATOR
Intervention: VerifyNow and LTA assessments
Number of subjects: 92
Study 34114623 — intervention group
Group type: COMPARATOR
Intervention: PK assessments in CKD patients
Number of subjects: 92
Study 34641897 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist pretreatment for 3 days before stimulation
Number of subjects: 136
Study 34641897 — intervention group
Group type: COMPARATOR
Intervention: Conventional GnRH antagonist protocol (without pretreatment)
Number of subjects: 136
Study 34641897 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist pretreatment
Number of subjects: 136
Study 34448875 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg phosphorus (NaH2PO4)
Number of subjects: 29
Study 34448875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 33622116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 4 × 5 minutes of individualized total occlusion pressure
Number of subjects: 30
Study 33622116 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol - 4 × 5 minutes using 20 mm Hg
Number of subjects: 30
Study 34152936 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor daylight photodynamic therapy (idl-PDT)
Number of subjects: 43
Study 34152936 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (cPDT)
Number of subjects: 43
Study 34758798 — intervention group
Group type: EXPERIMENTAL
Intervention: Older prisoner Health and Social Care Assessment and Plan (OHSCAP)
Number of subjects: 202
Study 34758798 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 202
Study 34758798 — intervention group
Group type: COMPARATOR
Intervention: Comparison between OHSCAP and TAU
Number of subjects: 202
Study 33180640 — intervention group
Group type: EXPERIMENTAL
Intervention: SQUAT (15 chair stands with calf raise)
Number of subjects: 14
Study 33180640 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK (2 min at 3.1 mph)
Number of subjects: 14
Study 33180640 — intervention group
Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 14
Study 32602079 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SLC)
Number of subjects: 193
Study 32602079 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic cholecystectomy (MLC)
Number of subjects: 193
Study 35524417 — intervention group
Group type: EXPERIMENTAL
Intervention: Extendable‐retractable helix leads (EHL)
Number of subjects: 280
Study 35524417 — intervention group
Group type: COMPARATOR
Intervention: Fixed‐helix leads (FHL)
Number of subjects: 280
Study 35524417 — intervention group
Group type: EXPERIMENTAL
Intervention: EHL
Number of subjects: 280
Study 35524417 — intervention group
Group type: COMPARATOR
Intervention: FHL
Number of subjects: 280
Study 35524417 — intervention group
Group type: EXPERIMENTAL
Intervention: EHL and FHL
Number of subjects: 280
Study 33610215 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) (20 Gy in five fractions or 30 Gy in ten fractions) plus usual care
Number of subjects: 199
Study 33610215 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 199
Study 33610215 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Number of subjects: 199
Study 35195549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (Strattera)
Number of subjects: 106
Study 35195549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 32157772 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 76
Study 32157772 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 76
Study 34284836 — intervention group
Group type: COMPARATOR
Intervention: TILS_dlPFC alone (n = 26)
Number of subjects: 112
Study 34284836 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + TILS_vmPFC (n = 29)
Number of subjects: 112
Study 34284836 — intervention group
Group type: COMPARATOR
Intervention: Exposure + sham TILS_vmPFC (n = 29)
Number of subjects: 112
Study 34284836 — intervention group
Group type: COMPARATOR
Intervention: Sham TILS_dlPFC alone (n = 28)
Number of subjects: 112
Study 33338988 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching program (30 min/d, 5 d/wk for 8 wk)
Number of subjects: 40
Study 32527152 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading system for restaurant sanitation
Number of subjects: 0
Study 35304401 — intervention group
Group type: EXPERIMENTAL
Intervention: Demanding albendazole
Number of subjects: 200
Study 35304401 — intervention group
Group type: EXPERIMENTAL
Intervention: Demanding amoxicillin
Number of subjects: 200
Study 35304401 — intervention group
Group type: COMPARATOR
Intervention: Control group (not demanding any medicine)
Number of subjects: 200
Study 32115311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression Prevention Training (APT)
Number of subjects: 228
Study 32115311 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Primary Care (EU-PC)
Number of subjects: 228
Study 33504434 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 8038
Study 33504434 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 8038
Study 32508327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg BID
Number of subjects: 118
Study 32508327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (historical control from 2CARE trial)
Number of subjects: 118
Study 35896793 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 35896793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33819217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exer-gaming for 30 minutes twice a week for 8 weeks
Number of subjects: 90
Study 33819217 — intervention group
Group type: COMPARATOR
Intervention: Balance training exercises twice a week for 8 weeks
Number of subjects: 90
Study 36425335 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with transfer factor capsules
Number of subjects: 61
Study 36425335 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with transfer factor capsules
Number of subjects: 61
Study 34400956 — intervention group
Group type: COMPARATOR
Intervention: Oral betamethasone therapy (3 mg, once a week) with placebo
Number of subjects: 36
Study 34400956 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate (15 mg, once a week) with placebo
Number of subjects: 36
Study 34400956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate 15 mg, once a week and betamethasone 3 mg, once a week)
Number of subjects: 36
Study 36226802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional combined furosemide and digoxin
Number of subjects: 80
Study 36226802 — intervention group
Group type: COMPARATOR
Intervention: Intralesional normal saline solution (Control)
Number of subjects: 80
Study 33639493 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrocautery
Number of subjects: 103
Study 33639493 — intervention group
Group type: COMPARATOR
Intervention: Plasma ablation
Number of subjects: 103
Study 33724296 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy radiotherapy and two cycles of XELOX (arm A)
Number of subjects: 140
Study 33724296 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy with concurrent capecitabine (arm B)
Number of subjects: 140
Study 32650732 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Assets Supporting Transitions (CAST) intervention
Number of subjects: 216
Study 32650732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 216
Study 33603097 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic carbon exposure (increase of 0.51 μg/m3)
Number of subjects: 83454
Study 33603097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium exposure (increase of 0.06 μg/m3)
Number of subjects: 83454
Study 33603097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 83454
Study 32339262 — intervention group
Group type: EXPERIMENTAL
Intervention: BaPoFi-TTE method for analyzing time-to-event data with censoring and toxicity outcomes.
Number of subjects: 0
Study 32339262 — intervention group
Group type: EXPERIMENTAL
Intervention: BaPoFi method for population finding with continuous or binary outcomes.
Number of subjects: 0
Study 32820320 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18918
Study 32820320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18918
Study 35001643 — intervention group
Group type: EXPERIMENTAL
Intervention: Active non-invasive vagus nerve stimulation
Number of subjects: 336
Study 35001643 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 336
Study 32706716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention app (n=73)
Number of subjects: 183
Study 32706716 — intervention group
Group type: COMPARATOR
Intervention: Active control app (n=110)
Number of subjects: 183
Study 35974347 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided online group singing (1 session per week for 12 weeks)
Number of subjects: 100
Study 35974347 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 100
Study 34304913 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC IBU/APAP 250 mg/500 mg
Number of subjects: 290
Study 34304913 — intervention group
Group type: EXPERIMENTAL
Intervention: IBU 250 mg
Number of subjects: 290
Study 34304913 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP 500 mg
Number of subjects: 290
Study 34304913 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC IBU/APAP 250 mg/500 mg, IBU 250 mg, APAP 500 mg
Number of subjects: 290
Study 34304913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 34304913 — intervention group
Group type: EXPERIMENTAL
Intervention: IBU cohort
Number of subjects: 290
Study 34304913 — intervention group
Group type: COMPARATOR
Intervention: FDC IBU/APAP 250 mg/500 mg, placebo
Number of subjects: 290
Study 32423576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1 g + 0.9% normal saline 100 mL)
Number of subjects: 102
Study 32423576 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (2 g + 0.9% normal saline 50 mL)
Number of subjects: 102
Study 32423576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TXA
Number of subjects: 102
Study 34262263 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPH ER TAB (amphetamine extended-release tablet)
Number of subjects: 35
Study 33089769 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with anlotinib (TC group)
Number of subjects: 82
Study 33089769 — intervention group
Group type: COMPARATOR
Intervention: TACE alone (TA group)
Number of subjects: 82
Study 32957900 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program (REP, 50‐60% of 1RM, for 40‐50 min) combined with metformin
Number of subjects: 57
Study 32957900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AEP, 50‐70% maxHR, for 40‐50 min) combined with metformin
Number of subjects: 57
Study 32957900 — intervention group
Group type: COMPARATOR
Intervention: Metformin without exercise intervention (Met group)
Number of subjects: 57
Study 33040806 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole plus flupenthixol/melitracen
Number of subjects: 140
Study 33040806 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 140
Study 35420554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination prevention (CP) including intensive testing, linkage campaigns, expanded ART, and voluntary male medical circumcision referrals
Number of subjects: 55000
Study 35420554 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 55000
Study 34620454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track and Standard Treatment Trial (FASTT)
Number of subjects: 286
Study 34620454 — intervention group
Group type: EXPERIMENTAL
Intervention: Trying to conceive without treatment
Number of subjects: 286
Study 34620454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination
Number of subjects: 286
Study 34620454 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous oocyte in vitro fertilization
Number of subjects: 286
Study 34620454 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes after FASTT
Number of subjects: 286
Study 34620454 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reproductive outcomes
Number of subjects: 286
Study 33684737 — intervention group
Group type: EXPERIMENTAL
Intervention: n−3 PUFA (2.2 g/day)
Number of subjects: 71
Study 33741075 — intervention group
Group type: EXPERIMENTAL
Intervention: SeqEnhDL deep learning framework
Number of subjects: 9
Study 33337602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cam-type FAI patients
Number of subjects: 16
Study 33337602 — intervention group
Group type: COMPARATOR
Intervention: Unilateral FAI patients
Number of subjects: 16
Study 33337602 — intervention group
Group type: COMPARATOR
Intervention: Control patients (asymptomatic hips)
Number of subjects: 16
Study 33007299 — intervention group
Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA) users
Number of subjects: 3
Study 33007299 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 3
Study 33007299 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women not using hormonal or intrauterine contraception
Number of subjects: 3
Study 33884767 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-30
Number of subjects: 0
Study 33884767 — intervention group
Group type: COMPARATOR
Intervention: Red ginseng extract
Number of subjects: 0
Study 33571959 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent endurance and strength training (n = 14)
Number of subjects: 25
Study 33571959 — intervention group
Group type: COMPARATOR
Intervention: Endurance training only (n = 11)
Number of subjects: 25
Study 35029748 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy with phycocyanin
Number of subjects: 60
Study 35029748 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy with toluidine blue O
Number of subjects: 60
Study 35029748 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch groups with aPDT
Number of subjects: 60
Study 35029748 — intervention group
Group type: COMPARATOR
Intervention: Control total etch groups
Number of subjects: 60
Study 35029748 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after thermocycling
Number of subjects: 60
Study 34083582 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-use change and topography
Number of subjects: 0
Study 34083582 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive maps of larval habitats
Number of subjects: 0
Study 34083582 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor analyses
Number of subjects: 0
Study 32576004 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat group (n=20)
Number of subjects: 40
Study 32576004 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (n=20)
Number of subjects: 40
Study 35296483 — intervention group
Group type: COMPARATOR
Intervention: Control message (Your coronavirus test result is negative)
Number of subjects: 1200
Study 35296483 — intervention group
Group type: EXPERIMENTAL
Intervention: Current NHS Test & Trace message (Your coronavirus test result is negative + Its likely you were not infectious when the test was done)
Number of subjects: 1200
Study 35296483 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated NHS T&T message (Your coronavirus test result is negative + Its likely you were not infectious when the test was done + But there is still a chance you may be infectious)
Number of subjects: 1200
Study 35296483 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated NHS T&T+infographic message (Your coronavirus test result is negative + Its likely you were not infectious when the test was done + But there is still a chance you may be infectious + infographic depicting residual risk)
Number of subjects: 1200
Study 35296483 — intervention group
Group type: EXPERIMENTAL
Intervention: All messages (including control)
Number of subjects: 1200
Study 33136005 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer biolimus-eluting stents (BP-BES)
Number of subjects: 2712
Study 33136005 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stents (DP-EES)
Number of subjects: 2712
Study 33136005 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer zotarolimus-eluting stents (DP-ZES)
Number of subjects: 2712
Study 36011692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-Based Diabetic Intervention (PDIM)
Number of subjects: 109
Study 36011692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109
Study 33373976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle mobilization with anterior tibia glide
Number of subjects: 117
Study 33373976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle mobilization with posterior tibia glide
Number of subjects: 117
Study 33373976 — intervention group
Group type: COMPARATOR
Intervention: Ankle mobilization with anterior and posterior tibia glide
Number of subjects: 117
Study 35871490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1.5 mg/ml)
Number of subjects: 60
Study 35871490 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone (20 mg/ml)
Number of subjects: 60
Study 33840229 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab single dose (30 mg)
Number of subjects: 56
Study 33840229 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab q4w (30 mg every 4 weeks for a total of three doses)
Number of subjects: 56
Study 33840229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56